Jazz Pharmaceuticals plc has grown revenue 6.9% a year over three years and 12% a year over five. Revenue growth, 3-year annual rate: +6.9% (Biotechnology median +17%). Revenue growth, 5-year rate: +12%, growth has slowed since the five-year average. Years of annual history on file: 17, FY2009 to FY2025, as filed.

JAZZJazz Pharmaceuticals plc

Healthcare

$218.41+70% 1Y

$218.41

$127.0052 weeks$261.72

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +13% year on year and operating margin widening (+27.0 points), but earnings down −315% year on year.

2 good, 1 to watch

Revenue trend+13% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +12% a year.

Earnings trend−315% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+27.0 points operating

Trailing-twelve-month operating margin, 19.6% now against -7.4% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is JAZZ growing?

Jazz Pharmaceuticals plc has grown revenue 6.9% a year over three years and 12% a year over five.

+6.9%

Revenue growth, 3-year annual rate · Biotechnology median +17% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +12%
Revenue growth, 5-year rate · +6.9% over three · growth has slowed since the five-year average
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed

Details›